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Protocol
AbstrACt
Introduction Patients with closed high-energy injuries 
associated with major trauma have surprisingly high 
rates of surgical site infection in incisions created during 
fracture fixation. One factor that may reduce the risk of 
surgical site infection is the type of dressing applied over 
the closed surgical incision. In this multicentre randomised 
clinical trial, negative-pressure wound therapy will be 
compared with standard dressings with outcomes of deep 
infection, quality of life, pain and disability.
Methods and analysis Adult patients presenting to 
hospital within 72 hours of sustaining major trauma, 
requiring a surgical incision to treat a fractured lower 
limb, are eligible for inclusion. Randomisation, stratified 
by trial centre, open/closed fracture at presentation 
and Injury Severity Score (ISS) ≤15 versus ISS ≥16 will 
be administered via a secure web-based service using 
minimisation. The random allocation will be to either 
standard wound management or negative-pressure wound 
therapy. Trial participants will usually have clinical follow-
up at the local fracture clinic for a minimum of 6 months, 
as per standard National Health Service practice. Diagnosis 
of deep infection will be recorded at 30 days. Functional, 
pain and quality of life outcome data will be collected 
using the Disability Rating Index, Douleur Neuropathique 
Questionnaire and Euroqol - 5 Dimension - 5 level (EQ-5D-
5L) questionnaires at 3 months and 6 months postinjury. 
Further data will be captured on resource use and any late 
postoperative complications. Longer term outcomes will 
be assessed annually for 5 years and reported separately.
Ethics and dissemination National Research Ethics 
Committee approved this study on 16 February 2016 16/
WM/0006. The National Institute for Health Research 
Health Technology Assessment monograph and a 
manuscript to a peer-reviewed journal will be submitted on 
completion of this trial. The results of this trial will inform 
clinical practice on the clinical and cost-effectiveness of 
the treatment of this injury.
trial registration number ISRCTN12702354; Pre-results.
bACkground 
Major trauma is the leading cause of death in 
people aged under 45 years and a significant 
cause of short-term and long-term morbidity. 
The National Audit Office (NAO) estimates 
that there are at least 20 000 cases of major 
trauma each year in England, resulting in 
5400 deaths, and many survivors suffer perma-
nent disabilities requiring long-term care. 
The NAO estimates that trauma costs the 
National Health Service (NHS) between £0.3 
and £0.4 billion a year for immediate treat-
ment. This does not include the cost of subse-
quent hospital treatments, rehabilitation, 
home care support or informal carers. The 
NAO estimate that the annual lost economic 
strength and limitations of this study
 ► Broad eligibility criteria to ensure generalisability.
 ► Deep infection data will be supplemented with pa-
tient-reported outcomes.
 ► Assessment of outcomes at multiple time points will 
allow for information on recovery profile.
 ► In addition to a comparison of clinical outcomes, a 
full cost-effectiveness evaluation will be performed.
 ► It will not be possible to blind patients to their allo-
cated treatment, as the type of wound dressing will 
be clearly visible.
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output from traumatic injury is between £3.3 billion and 
£3.7 billion.
Fractures of the limbs are extremely common injuries, 
with 85% of major trauma patients sustaining serious 
limb injuries.1 In open fractures of the lower limb, where 
the broken bone is exposed to the environment by a 
breach in the skin, the risk of infection is particularly 
high.1 However, even in closed high-energy injuries asso-
ciated with major trauma, the rate of infection remains 
high. For example, tibial plateau fractures are associated 
with average infection rates of up to 27%,2–6 while pilon 
fractures have an incidence of deep infections ranging 
from 5% to 40%.7–10 If surgical site infection (SSI) does 
occur, treatment frequently continues for years after the 
initial injury. This often involves prolonged courses of 
antibiotics, with attendant risk of antibiotic resistance in 
chronic wounds, and a huge healthcare cost associated 
with such injuries. A US study found that the average cost 
associated with infection was $163 000 if the limb could be 
salvaged and $500 000+ where amputation was necessary, 
and these only represent a fraction of the subsequent 
personal and societal costs.11
Major trauma patients are at greater risk of infection 
due to several factors, including the presence of anti-
biotic resistant organisms in the intensive therapy unit 
(ITU) and high-dependency environment. Furthermore, 
the presence of a wound haematoma or postoperative 
wound leak oozing may predispose to infection in wounds 
created by surgical incisions. One of the factors that may 
reduce the risk of SSI is the type of dressing applied over 
the closed incision at completion of the operative proce-
dure. Dressings may reduce bacterial ingress into the 
wound. The published literature suggests that the type 
of dressing applied to the wound influences the healing 
process itself.12 This trial concerns the type of dressing 
that is applied to the closed surgical incision at the end of 
the operation.
Traditionally, the surgical incision is covered with an 
adhesive dressing or gauze maintained in place with a 
bandage to protect the wound from contamination from 
the outside environment. These ‘standard dressings’ 
have been used throughout the NHS and in military prac-
tice for many years. Negative-pressure wound therapy 
(NPWT) or topical negative pressure is an alternative 
form of dressing that may be applied to closed surgical 
incisions. In this treatment, an ‘open-cell’ solid foam 
overlies the incision and is covered with a semipermeable 
membrane, which is only permeable to gas. A sealed tube 
is used to connect the foam to a pump, which creates a 
partial vacuum over the wound. This negative-pressure 
therapy provides a sealed environment, preventing bacte-
rial ingress and removes blood and serous fluid exuding 
from the wound. The application of negative pressure to 
the foam leads to the application of positive pressure to 
the wound bed and has been shown to reduce the inci-
dence of wound haematoma.13 Recent laboratory studies 
suggest that NPWT shifts the cytokine profile to being 
less inflammatory, potentially promoting the production 
of proangiogenic growth factors and enzymes respon-
sible for matrix remodelling, leading to improved wound 
healing.12 However, NPWT for closed wounds is consid-
erably more expensive than traditional wound dressings. 
There has been only one randomised trial comparing 
standard wound dressing with NPWT for patients with 
closed surgical wounds following major trauma to the 
lower limb.13 This trial demonstrated a reduction in the 
rate of late/deep wound infection in the group of patients 
treated with NPWT (9%) versus the standard dressing 
group (15%). However, the reduction was of borderline 
statistical significance (p=0.049), and the study has been 
criticised in the subsequent Cochrane review for method-
ological flaws.14
The recent Cochrane review for surgical wounds 
concluded that ‘it is still not clear whether NPWT promotes 
faster healing and reduces complications associated with clean 
surgery’. ‘Given the cost and widespread use of NPWT, there is 
an urgent need for suitably powered, high-quality trials to eval-
uate the effects of the newer NPWT products that are designed for 
use on clean, closed surgical incisions. Such trials should focus 
initially on wounds that may be difficult to heal’.14 The Wound 
Healing in Surgery for Trauma (WHIST) Trial aims to 
address this evidence gap.
good ClInICAl PrACtICE
The trial will be carried out in accordance with Medical 
Research Council Good Clinical Practice and applicable 
UK legislation using the following protocol.
ConsolIdAtEd stAndArds of rEPortIng trIAls 
(Consort)
The trial will be reported in line with the CONSORT state-
ment using the non-pharmacological treatment interven-
tions extension.
trial design
Aim
The aim of this pragmatic randomised controlled trial 
is to compare NPWT with standard wound dressings for 
the treatment of surgical incisions associated with major 
trauma to the lower limb on outcomes of deep infection, 
quality of life, pain and disability.
The primary objective for the RCT is:
To quantify and draw inferences on differences in 
the rate of ‘deep SSI’ of the lower limb in the 30 days 
after randomisation between treatment arms of standard 
wound dressing versus NPWT. Any wound infection that 
requires continuing medical intervention or has already 
led to amputation at the 30-day review will be considered 
a ‘deep’ infection.
The secondary objectives are:
i. To quantify and draw inferences on observed differ-
ences in the Disability Rating Index (DRI) in the 6 
months after the major trauma.
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ii. To quantify and draw inferences on observed differ-
ences in general health-related quality of life in the 6 
months after the major trauma.
iii. To quantify and draw inferences on the quality of 
wound healing, using a validated, patient-reported 
assessment of the scar. The patient-reported assess-
ment will be supplemented with photographs taken 
at 6 weeks to objectively assess wound healing and ap-
parent signs of infection.
iv. To determine the number and nature of complica-
tions in the first 6 months after the major trauma: in-
cluding chronic pain, deep SSI at 90 days and further 
surgical interventions related to the injury.
v. To investigate the cost-effectiveness of NPWT versus 
standard dressing for wounds associated with major 
trauma to the lower limbs.
outcome measures
The primary outcome measure for this study is deep SSI; 
we will use the Centers for Disease Control and Preven-
tion (CDC) definition of a ‘deep SSI’, that is, a wound 
infection involving the tissues deep to the skin that occurs 
within 30 days of injury.15
The treating clinical team will make the diagnosis of 
‘infection’, as per routine clinical practice. The treating 
clinicians will not be part of the research team. As the 
prompt diagnosis and treatment of infection is funda-
mental to the patient’s routine clinical care, the treating 
surgeon/clinician will always document such a change 
in management in the patient’s medical record. The 
medical records will be reviewed by an independent 
research associate who will complete the clinical reporting 
forms, which will include the specific criteria used by the 
CDC to define a ‘deep SSI’. Any infection that requires 
continuing medical intervention or has already led to 
amputation at or after the 30-day review will be consid-
ered a deep infection.
The secondary outcome measures in this trial are:
Disability Rating Index
DRI is measured using a self-administered, 12-item visual 
analogue scale questionnaire assessing the patients’ own 
rating of their disability.16 This measure was chosen as 
it addresses gross body movements rather than specific 
joints or body segments. Therefore, it will capture func-
tion and disability associated with different fractures and 
injuries of the lower limbs.
EuroQol EQ-5D-5L
The EuroQol EQ-5D is a validated measure of health-re-
lated quality of life, consisting of a five dimension health 
status classification system and a separate visual analogue 
scale.17 An updated version of the EQ-5D with five response 
levels, the EQ-5D-5L, has recently been developed to 
enhance the responsiveness of the instrument to changes 
in patient health.18 Responses to the health status classifi-
cation system will be converted into multiattribute utility 
(MAU) scores using tariffs currently under development 
for England.19 These MAU scores will be combined with 
survival data to generate quality-adjusted life year (QALY) 
profiles for the purposes of the economic evaluation. The 
EQ-5D has been validated to be completed by a patient’s 
proxy in case of continued impaired capacity.
Wound healing
A patient-reported scar assessment will be collected using 
the patient scale from the Patient and Observer Scar 
Assessment Scale20 consisting of six questions regarding 
different aspects of the scar, as well as an overall assess-
ment of the scar. This will be used to provide a subjec-
tive patient assessment of wound healing. An objective 
assessment of wound healing using a standardised photo-
graph of the wound from the 30-day review will be evalu-
ated by two independent experienced assessors who are 
blind to the treatment allocation. Patients will also be 
asked to self-report any treatment for infection, which 
will be cross-referenced with the participant’s medical 
record. This will allow us to report deep infection at later 
time points, for example, at 90 days.
Complications
Chronic pain: the proportion of patients reporting 
chronic pain postinjury with neuropathic characteris-
tics will be measured using the Douleur Neuropathique 
Questionnaire (DN4).21 Chronic pain after surgery and 
trauma is common and disabling, but no previous studies 
have assessed the prevalence of persistent painful neuro-
pathic characteristics after lower limb fracture. The inter-
view versions of the DN4 is a short validated neuropathic 
pain screening tool comprising seven questions. This 
screening tool is recommended for use by the Interna-
tional Association for the Study of Pain.22 Scores of 3 or 
greater are likely to be indicative of neuropathic pain. 
Patients will also be asked to self-report (or a consultee 
on their behalf, in case of continued impaired capacity) 
at each of the follow-up points on wound healing compli-
cations, any treatment for infection and any medical/
surgical intervention related to infection associated with 
their surgical wound. Any self-report of treatment for 
infection will be cross-referenced with the participant’s 
medical record. This will allow us to report deep infec-
tion at later time points, for example, at 90 days. All other 
postoperative complications and surgical interventions 
related to the index wound will be recorded.
resource use 
Resource use will be monitored for the economic anal-
ysis. Unit cost data will be obtained from national data-
bases such as the British National Formulary and Personal 
Social Services Research Unit Costs of Health and Social 
Care.23 Where these are not available, the unit cost will 
be estimated in consultation with the hospital finance 
department. The cost consequences following discharge, 
including NHS costs and patients’ out-of-pocket expenses, 
will be recorded via a short questionnaire, which will 
be administered at 3 and 6 months postmajor trauma. 
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Patient self-reported (or consultee reported) information 
on service use has been shown to be accurate in terms of 
the intensity of use of different services.24
data collection
Table 1 displays the time points when outcome measures 
are being collected.
For the purposes of long-term follow-up, patients will 
subsequently be contacted on an annual basis for 5 years 
to complete the EQ-5D-5L, DRI and DN4 questionnaires. 
Longer term follow-up will be reported separately.
sample size
There has only been one previous randomised trial to 
compare NPWT to standard dressings for surgical inci-
sions associated with major trauma to the lower limb. 
This trial indicated that the rate of ‘late’ (deep) infection 
was 15% in the standard dressing group versus 9% in the 
NPWT group.13
In the absence of a ‘Minimum Clinically Important 
Difference’ for deep wound infection, we surveyed 
surgeons in the UK Orthopaedic Trauma Society who 
perform surgery for major trauma to the limbs (unpub-
lished data 2015). The survey showed that those who 
responded to the survey considered that a 6% reduction 
in the rate of ‘deep infection’ would, universally, be suffi-
cient to change clinical practice with regard to the choice 
of wound dressing.
Therefore, assuming a reduction in the proportion of 
patients having a deep infection from 15% to 9%, 615 
patients would be required in each group to provide 90% 
power at the 5% level. Our previous experience in clin-
ical trials of lower limb fracture surgery for major trauma 
indicates that up to 20% of primary outcome data may be 
lost during the follow-up period, due to death and loss to 
follow-up. Therefore, we aim to recruit 1540 patients in 
total for this trial.
Methodology
Screening
Patients will be screened from the emergency depart-
ment or trauma unit from participating trial centres. 
Throughout the study, screening logs will be kept at 
each site to determine the number of patients assessed 
for eligibility and any reasons for any exclusion. Patients 
who decline to participate or withdraw from the study will 
be given the opportunity to discuss/inform the research 
team of their reasoning behind their decision not to take 
part.
The patient’s routine imaging on admission will be 
used, including any ‘Major Trauma CT scan’, and asso-
ciated ‘secondary survey’ to identify the patient’s inju-
ries and calculate the Injury Severity Score (ISS) (15 
or less vs 16 or more) before randomisation. All major 
trauma patients in England are automatically considered 
for entry onto the national Trauma Audit and Research 
Network (TARN) database, which requires the calcula-
tion of the ISS. Therefore, all centres are familiar with 
the use of this major trauma scoring system.
Eligibility
Patients will be eligible for WHIST if:
 ► They are aged 16 years or older.
 ► Present to hospital within 72 hours of injury.
 ► They have a major trauma injury and/or TARN 
eligible injury as defined by eligibility for the UK 
TARN database.
 ► They have a lower limb fracture requiring a surgical 
incision.
Some patients have major trauma affecting just one 
limb, for example, heel, pilon and tibial plateau fractures. 
Since the wounds associated with these injuries are always 
at risk, we will include these injuries even if the patient is 
subsequently not included in TARN.
Patients will be excluded from participation in WHIST 
if:
 ► They have an open fracture of the lower limb that 
cannot be closed primarily.
 ► There is evidence that the patient would be unable to 
adhere to trial procedures or complete questionnaires. 
Patients who sustain injuries to areas of the body other 
than the lower limbs, which may affect the primary 
outcome measure, will have their other injuries docu-
mented but will still be included in the analysis. For 
patients with more than one lower limb injury, only the 
most severe wound will be included as the ‘WHIST’ 
wound in the trial. It will be up to the surgeon’s discretion 
to decide which injury is the most severe.
Consent to participating
Many patients with major trauma will be operated on 
immediately or on the next available trauma oper-
ating list. Some patients may be unconscious, all will be 
distracted by their injury and its subsequent treatment 
and all will have had large doses of opiates for pain relief, 
potentially affecting their ability to process study-related 
Table 1 Outcome collection
Time point Data collection
Baseline DRI and EQ-5D preinjury and contemporary.
30 days Deep infection, complication records, scar 
assessment, operative record and photograph 
of limb wound.
3 months DRI, EQ-5D, DN4, scar assessment, record 
of complications/rehabilitation or other 
interventions and economics questionnaire.
6 months DRI, EQ-5D, DN4, scar assessment, record 
of complications/rehabilitation or other 
interventions and economics questionnaire.
12 months DRI, EQ-5D, DN4 and record of complications/
further interventions.
2, 3, 4 and 
5 years
DRI, EQ-5D, DN4 and record of complications/
further interventions.
DN4, Douleur Neuropathique Questionnaire; DRI, Disability Rating 
Index; EQ-5D, Euroqol-5 Dimension questionnaire.
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information. Similarly, patients’ next of kin, carers and 
friends are often anxious at this time and may have diffi-
culty in considering the large amounts of information that 
they are given about the injury and plan for treatment. 
In this emergency situation, the focus is on obtaining 
consent for surgery (where possible) and informing the 
patient and any next of kin about immediate clinical care. 
The consent procedure for this trial will reflect that of 
the surgery, with the attending clinician assessing capacity 
before taking consent for the surgical procedure, and 
this capacity assessment then being used to decide on the 
proper approach to consenting to the WHIST study. An 
appropriate method, in line with the mental capacity act 
and as approved by the National Research Ethics Service, 
will then be used to gain either prospective or retrospec-
tive consent from the patient or appropriate consultee by 
an appropriately delegated member of the research team.
Randomisation
The treating surgeon will confirm participant eligibility 
at the end of the operative procedure but before the 
wound dressing is applied. Randomisation will be on a 1:1 
basis, using a validated computer randomisation program 
managed centrally by the Oxford Clinical Trials Research 
Unit (OCTRU). A minimisation algorithm will be used 
to ensure balanced allocation of patients across the two 
treatment groups, stratified by trial centre, open or closed 
fracture at presentation and ISS ≤15 versus ISS ≥16. The 
first 30 participants will be randomised using simple 
randomisation to seed the minimisation algorithm 
(generated by the trial statistician), and the minimis-
ation algorithm will have probabilistic element of 0.8 
introduced to ensure unpredictability of the treatment 
assignment. After the randomisation is received electron-
ically by the surgical team, the allocated treatment can be 
administered immediately.
Postrandomisation withdrawals/exclusions
Participants will be excluded in the postrandomisation 
phase if it is later established that they are unable to 
adhere to trial procedures or complete questionnaires.
Participants may decline to continue to take part in the 
trial at any time without prejudice. A decision to decline 
consent or withdraw will not affect the standard of care 
the patient receives.
Blinding
As the wound dressings and topical devices are clearly 
visible, the treating surgeon and trial participants cannot 
be blinded to treatment allocation. However, the treating 
surgeons will not be involved in study follow-up assess-
ments or data collection for the trial. Data from clinical 
reporting forms will be entered onto a central database 
administered by a data clerk independent of the clinical 
team in the trial central office. Wound photographs taken 
at outpatient clinic at approximately 30-day postsurgery 
will be reviewed independently by two experienced asses-
sors blinded to the treatment allocation.
trial treatments
Patients with a fracture of the lower limb associated with 
major trauma usually have surgery on the next available 
trauma operating list. Some patients may be transferred to 
a major trauma centre for definitive care—within the first 
48 hours of injury—but will still have their initial surgery 
as soon as possible. All patients will receive general or 
regional anaesthesia. At the end of the initial operation, 
a dressing is applied to the surgical wound. WHIST will 
compare two types of wound dressing: standard dressing 
versus NPWT.
Standard dressing
The standard dressing for a surgical wound comprises a 
non-adhesive layer applied directly to the wound, which 
is then covered by a sealed dressing or bandage. The stan-
dard dressing does not use ‘negative pressure’. The exact 
details of the materials used will be left to the discretion 
of the treating surgeon as per their routine practice, but 
the details of each dressing applied will be recorded.
Negative-pressure wound therapy
The NPWT dressing uses an ‘open-cell’ solid foam, which 
is laid onto the wound as an intrinsic part of a sealed 
dressing. A sealed tube connects the dressing to a built-in 
mini-pump that creates a partial vacuum over the wound.
The NPWT dressing will be applied to the wound at the 
end of the operation according to the treating surgeon’s 
normal practice and the dressing manufacturer’s instruc-
tions. The wound may be redressed again on the ward; 
any further wound dressing will be recorded and will 
follow the allocated treatment unless otherwise clinically 
indicated.
Postoperative rehabilitation
Patients will usually be reviewed at 3 and 6 months, as 
per routine practice after this type of injury. Details about 
rehabilitation and additional follow-up appointments 
will be recorded but left entirely to the discretion of the 
treating clinicians, as the type of injury will vary between 
patients.
Adverse event management
Serious adverse events (SAEs) will be entered onto the 
SAE reporting form and reported to the central study 
team. However, some adverse events are foreseeable as 
part of the proposed treatment and will not be reported 
on an SAE reporting form but recorded on a complica-
tions form. These events include: any complications of 
anaesthesia or surgery (wound infection, bleeding or 
damage to adjacent structures such as nerves, tendons 
and blood vessels, delayed unions/non-unions, delayed 
wound healing, further surgery to remove/replace metal-
work and thromboembolic events). All participants expe-
riencing SAEs will be followed up as per protocol until 
the end of the trial.
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End of trial
The end of the main phase of the trial will be defined as 
the collection of final 6-month outcome data from the 
last participant. Longer term follow-up will be reported 
separately.
Analysis
Statistical analysis
Baseline characteristics and outcome measures will be 
reported overall and separately for the two treatment 
arms using standard statistical summaries (eg, medians 
and ranges or means and variances, or proportions 
and percentages, dependent on the distribution of the 
outcomes) including graphical presentation where 
appropriate.
The primary analysis will investigate differences in the 
primary outcome measure, the proportion of patients with 
deep SSI, at 30-day postoperation. Although we have no 
reason to expect that clustering effects will be important 
for this study, in reality, the data will be hierarchical in 
nature, with patients naturally clustered into groups by 
recruiting centre. Therefore, we will account for this 
by generalising the conventional logistic (fixed-effects) 
regression approach to a mixed-effects logistic regres-
sion analysis. This model will be used to assess differences 
in the rate of deep SSI between the study intervention 
groups, with results presented as ORs with associated 95% 
CIs. The mixed-effects model will include a random effect 
to account for any heterogeneity in response due to the 
recruitment centre and fixed effects to adjust for open 
versus closed fractures and the ISS, participant age and 
gender.
An identically structured and formulated mixed-ef-
fects linear or logistic regression model (as appropriate) 
will be used to assess the effects of the interventions on 
secondary outcomes DRI and EQ-5D-5L (at both 3 and 
6 months and for the long-term follow-up). Supplemen-
tary analyses for these outcomes will include using area 
under the curve summary statistics calculated from the 
mixed model parameter estimates to provide an overall 
estimate of recovery over time.25 Other dichotomous 
outcome variables, such as complications related to the 
trial interventions, will be analysed in the same manner as 
the primary outcome. Temporal patterns of any compli-
cations will be presented graphically, and if appropriate a 
time-to-event analysis (Kaplan-Meier survival analysis) will 
be used to assess the overall risk and risk within individual 
classes of complications.
It seems likely that some data may not be available 
due to voluntary withdrawal of patients, lack of comple-
tion of individual data items or general loss to follow-up. 
Missing data will be minimised, and the reasons for 
missing data will be ascertained and reported separately 
by treatment group. The amount, nature and pattern of 
missing data will be carefully considered, and missing 
data will be imputed, using multiple imputation if 
appropriate.
The primary population for analysis will be on an inten-
tion-to-treat (ITT) basis, that is, analysed as they were 
randomised. In addition to the ITT analyses, sensitivity 
analyses including on the per-protocol population and to 
assess the missing data assumption if missing data impu-
tation is used will also be undertaken and reported in 
parallel to, but subsidiary to, the main analyses.
About 1%–2% of patients are expected to die during 
follow-up, so this is unlikely to be a serious cause of bias. 
If appropriate, we will conduct a supplementary anal-
ysis taking account of the competing risk of death, using 
methods described by Varadhan et al.26
All reported tests will be two sided and considered to 
provide evidence for a significant difference if p values 
are less than 0.05 (5% significance level).
A detailed statistical analysis plan (SAP) will be agreed 
with the Data Safety and Monitoring Committee (DSMC) 
at the commencement of or early in the study. This 
will be updated prior to the final data-lock following a 
blinded analysis of the data. Any subsequent changes to 
the analysis outlined in the SAP will be clearly stated and 
justified in the final report. Interim analyses of efficacy 
outcomes are not planned and will be performed only 
where requested by the independent DSMC.
Analyses will be undertaken using validated statistical 
software such as Stata (http://www. stata. com) or the soft-
ware package R (http://www. r- project. org/).
Economic evaluation
An economic evaluation will be integrated into the trial 
design. The economic evaluation will be conducted from 
the recommended NHS and personal social services 
perspective.23 Data will be collected on the health and 
social service resources used in the treatment of each 
trial participant during the period between rando-
misation and 6 months postrandomisation. Trial data 
collection forms will record the duration of each form 
of hospital care, surgical procedures, adjunctive inter-
ventions, medication profiles, tests and procedures. If 
required, information on additional staff and material 
inputs associated with clinical complications will be 
obtained directly from patient and clinical records. At 3 
and 6 months postrandomisation, trial participants will 
be asked to complete postal questionnaires profiling 
hospital (inpatient and outpatient) and community 
health and social care resource use and, for the purposes 
of sensitivity analysis, out-of-pocket expenditures and 
costs associated with lost productivity. Current UK unit 
costs will be applied to each resource item to value total 
resource use in each arm of the trial. Per diem costs for 
hospital care, delineated by level or intensity of care, 
will be calculated by the health economics researcher 
using data from detailed questionnaires completed by 
the local finance departments, giving cost data and 
apportioning these to different categories of patient 
using a ‘top-down’ methodology. The unit costs of clin-
ical events that are unique to this trial will be derived 
from the hospital accounts of the trial participating 
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centres, although primary research that uses estab-
lished accounting methods may also be required. The 
unit costs of community health and social services will 
largely be derived from national sources, although 
some calculations from first principles using established 
accounting methods may also be required.27 Responses 
to the EQ-5D-5L will be converted into multiattribute 
utility scores using the algorithm currently under devel-
opment to reflect societal preferences in England.19 28 29 
Crosswalking algorithms will be employed to generate 
supplementary utility values comparable with those 
derived from the EQ-5D-3L instrument.18
An incremental cost-effectiveness analysis, expressed 
in terms of incremental cost per QALY gained, will 
be performed. Results will be presented using incre-
mental cost-effectiveness ratios and cost-effectiveness 
acceptability curves generated via non-parametric boot-
strapping. This accommodates sampling (or stochastic) 
uncertainty and varying levels of willingness to pay for 
an additional QALY. Issues with missing values, if they 
arise, will be accommodated using multiple imputation 
methods in line with the approach used in the clinical 
component of the trial.
trIAl ovErsIght
The day-to-day management of the trial will be the respon-
sibility of the Clinical Trial Manager, based at Nuffield 
Department of Orthopaedics, Rheumatology and Muscu-
loskeletal Sciences and supported by the OCTRU staff. 
This will be overseen by the trial management group, 
who will meet monthly to assess progress. It will also be 
the responsibility of the clinical trial manager to under-
take training of the research associates at each of the trial 
centres. The trial statistician and health economist will be 
closely involved in setting up data capture systems, design 
of databases and clinical reporting forms.
A Trial Steering Committee (TSC) and a DSMC will be 
set up. The study DSMC will adopt a DAMOCLES charter, 
which defines its terms of reference and operation in rela-
tion to oversight of the trial. They will not be asked to 
review any formal interim comparative analyses of effec-
tiveness. They will, however, see copies of data accrued to 
date or summaries of that data by treatment group, and 
they will assess the screening algorithm against the eligi-
bility criteria. They will also consider emerging evidence 
from other related trials or research and review-related 
SAEs that have been reported. They may advise the chair 
of the TSC at any time if, in their view, the trial should 
be stopped for ethical reasons, including concerns about 
participant safety. DSMC meetings will be held at least 
annually during the recruitment phase of the study.
Quality control
The study may be monitored, or audited in accordance 
with the current approved protocol, relevant regulations 
and standard operating procedures by the host organi-
sation, sponsor or appropriate regulatory authorities. A 
monitoring plan will be developed according to OCTRU 
standard operating procedures, which involves a risk 
assessment. The monitoring activities are based on the 
outcome of the risk assessment and may involve central 
monitoring and site monitoring.
dIssEMInAtIon
The study monograph for the National Institute for 
Health Research Health Technology Assessment will be 
prepared by the trial management team within 3 months 
of completion of the trial. A manuscript for a high-impact 
peer-reviewed journal will be prepared simultaneously, 
which will allow for the results to be disseminated across 
the orthopaedic and rehabilitation communities, the 
wider medical community, National Institute for Health 
and Care Excellence and policy makers. Authorship will 
be determined in accordance with the ICMJE guidelines, 
and other contributors will be acknowledged. The results 
of this trial will substantially inform clinical practice on 
the clinical and cost-effectiveness of the treatment of this 
injury. The results of this project will be disseminated 
to patients via patient-specific newsletters and through 
local mechanisms at all participating centres, and a lay 
summary of the results will be available on the study 
website.
PAtIEnt And PublIC InvolvEMEnt
A series of formal qualitative interviews with patients and 
clinicians were performed in the development of this trial. 
The views of patients were used to inform and refine the 
trial interventions and processes. Two of the patients who 
contributed during the development work have agreed to 
act as lay representatives on the trial management team.
Towards the end of the trial, the lay representatives 
will lead the dissemination of the findings of this study 
through the wider audience. They will lead in the devel-
opment of any material, including leaflets and website 
information used for this purpose.
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